{"id":"https://openalex.org/W2964695103","doi":null,"title":"Synthesis and Characterization of Long-Acting Rilpivirine Prodrugs","display_name":"Synthesis and Characterization of Long-Acting Rilpivirine Prodrugs","publication_year":2019,"publication_date":"2019-01-01","ids":{"openalex":"https://openalex.org/W2964695103","mag":"2964695103"},"language":"en","primary_location":{"id":"pmh:oai:digitalcommons.unmc.edu:etd-1393","doi":null,"is_oa":false,"landing_page_url":"https://digitalcommons.unmc.edu/etd/390","pdf_url":null,"source":{"id":"https://openalex.org/S7407097584","display_name":"DigitalCommons@UNMC","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I59130452","host_organization_name":"University of Nebraska Medical Center","host_organization_lineage":["https://openalex.org/I59130452"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Theses & Dissertations","raw_type":"text"},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5051999877","display_name":"James R. Hilaire","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"James R. Hilaire","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5051999877"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.6723999977111816,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.6723999977111816,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":0.20059999823570251,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10920","display_name":"Advanced Drug Delivery Systems","score":0.10140000283718109,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/rilpivirine","display_name":"rilpivirine","score":0.9449999928474426},{"id":"https://openalex.org/keywords/prodrugs","display_name":"prodrugs","score":0.9319999814033508},{"id":"https://openalex.org/keywords/long-acting-antiretrovirals","display_name":"long-acting antiretrovirals","score":0.9909999966621399},{"id":"https://openalex.org/keywords/hiv-1","display_name":"HIV-1","score":0.8510000109672546},{"id":"https://openalex.org/keywords/nanoformulations","display_name":"nanoformulations","score":0.9589999914169312},{"id":"https://openalex.org/keywords/injectable-dosage-forms","display_name":"injectable dosage forms","score":0.7509999871253967},{"id":"https://openalex.org/keywords/tissue-distribution","display_name":"tissue distribution","score":0.859000027179718},{"id":"https://openalex.org/keywords/plasma-half-life","display_name":"plasma half-life","score":0.6930000185966492},{"id":"https://openalex.org/keywords/antiretroviral-therapy","display_name":"antiretroviral therapy","score":0.7960000038146973},{"id":"https://openalex.org/keywords/cabotegravir","display_name":"cabotegravir","score":0.8109999895095825},{"id":"https://openalex.org/keywords/sustained-release","display_name":"sustained drug release","score":0.6420000195503235}],"concepts":[{"id":"https://openalex.org/C2778723075","wikidata":"https://www.wikidata.org/wiki/Q421547","display_name":"Rilpivirine","level":5,"score":0.9311912059783936},{"id":"https://openalex.org/C108215921","wikidata":"https://www.wikidata.org/wiki/Q603741","display_name":"Prodrug","level":2,"score":0.5751660466194153},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.3917274475097656},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3350352644920349},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.23580852150917053},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.15975689888000488},{"id":"https://openalex.org/C3013748606","wikidata":"https://www.wikidata.org/wiki/Q15787","display_name":"Human immunodeficiency virus (HIV)","level":2,"score":0.08408808708190918},{"id":"https://openalex.org/C2993143319","wikidata":"https://www.wikidata.org/wiki/Q583050","display_name":"Antiretroviral therapy","level":4,"score":0.0},{"id":"https://openalex.org/C142462285","wikidata":"https://www.wikidata.org/wiki/Q2528140","display_name":"Viral load","level":3,"score":0.0}],"mesh":[],"locations_count":2,"locations":[{"id":"pmh:oai:digitalcommons.unmc.edu:etd-1393","doi":null,"is_oa":false,"landing_page_url":"https://digitalcommons.unmc.edu/etd/390","pdf_url":null,"source":{"id":"https://openalex.org/S7407097584","display_name":"DigitalCommons@UNMC","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I59130452","host_organization_name":"University of Nebraska Medical Center","host_organization_lineage":["https://openalex.org/I59130452"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Theses & Dissertations","raw_type":"text"},{"id":"mag:2964695103","doi":null,"is_oa":false,"landing_page_url":"https://digitalcommons.unmc.edu/etd/390/","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9537000060081482,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2972081238","https://openalex.org/W2972997041","https://openalex.org/W2395339327","https://openalex.org/W2803558969","https://openalex.org/W2895682652","https://openalex.org/W3044310620","https://openalex.org/W2106408660","https://openalex.org/W2796858489","https://openalex.org/W2765161131","https://openalex.org/W2056424254"],"abstract_inverted_index":{"Antiretroviral":[0],"therapy":[1],"(ART)":[2],"requires":[3],"lifelong":[4],"daily":[5],"dosing":[6,45,83],"to":[7,29,90,108,124,193],"suppress":[8],"viral":[9,91],"replication,":[10],"restore":[11],"or":[12,41],"maintain":[13],"immune":[14],"function":[15],"and":[16,57,60,79,87,114,163,168,188,200],"improve":[17,189],"quality":[18],"of":[19,50,66,73,100,103],"life.":[20],"As":[21],"an":[22,35],"alternative,":[23],"long-acting":[24],"(LA)":[25],"antiretrovirals":[26],"(ARVs)":[27],"aim":[28],"deliver":[30],"therapeutic":[31],"drug":[32,111],"concentrations":[33,113,138],"over":[34],"extended":[36,44],"period,":[37],"ultimately":[38],"requiring":[39],"monthly":[40],"even":[42],"more":[43],"intervals.":[46],"Specifically,":[47,133],"the":[48,64,98,140,185],"success":[49],"recent":[51],"clinical":[52],"trials":[53],"examining":[54],"LA":[55,74,128],"cabotegravir":[56],"rilpivirine":[58],"(CAB":[59],"RPV":[61,104,136,180,195],"LA)":[62],"highlight":[63],"advent":[65],"these":[67,175],"novel":[68],"HIV-1":[69],"therapeutics.":[70],"Further":[71],"optimization":[72],"dosage":[75,130],"forms":[76],"are":[77],"required":[78],"rests":[80],"upon":[81],"improving":[82],"frequency,":[84],"injection":[85,155],"volumes":[86],"tissue":[88,116,150,190],"distribution":[89,191],"compartments.":[92],"To":[93],"this":[94],"end,":[95],"we":[96],"report":[97],"synthesis":[99],"a":[101,126,148],"library":[102],"prodrugs":[105,181],"specifically":[106],"designed":[107],"provide":[109,177],"sustained":[110],"plasma":[112,137],"enhance":[115],"distribution.":[117],"Lead":[118],"prodrug":[119],"candidate":[120],"M3RPV":[121],"was":[122],"nanoformulated":[123,179,194],"develop":[125],"stable":[127],"injectable":[129],"form":[131],"(NM3RPV).":[132],"NM3RPV":[134,160],"provided":[135,161],"above":[139],"PA-IC90":[141],"for":[142],"25":[143],"weeks,":[144],"while":[145],"concurrently":[146],"generating":[147],"substantial":[149],"depot":[151],"after":[152],"in":[153,156,166],"single":[154],"BALB/cJ":[157],"mice.":[158],"Furthermore,":[159],"13":[162],"26-fold":[164],"increases":[165],"t1/2":[167],"MRT":[169],"compared":[170,192],"with":[171],"NRPV":[172],"respectively.":[173],"Therefore,":[174],"results":[176],"proof-of-concept":[178],"can":[182],"effectively":[183],"extend":[184],"apparent":[186],"half-life":[187],"(NRPV),":[196],"warranting":[197],"further":[198],"investigation":[199],"optimization.":[201]},"counts_by_year":[],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2019-08-13T00:00:00"}